Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity

PD-L1 has two receptors: PD-1 and CD80. Previous reports assumed that PD-L1 and CD80 interacted in trans, but recent reports showed that only cis PD-L1/CD80 interactions existed, and prevention of cis PD-L1/CD80 interactions on antigen-presenting cells (APCs) reduced antitumor immunity via augmentin...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yuankun, Song, Qingxiao, Cassady, Kaniel, Lee, Michael, Tang, Haidong, Zheng, Moqian, Wang, Bixin, Schones, Dustin E., Fu, Yang-Xin, Riggs, Arthur D., Martin, Paul J., Feng, Ru, Zeng, Defu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2023
Materias:
Biological sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120074/
https://www.ncbi.nlm.nih.gov/pubmed/37036990
http://dx.doi.org/10.1073/pnas.2205085120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10120074/
https://www.ncbi.nlm.nih.gov/pubmed/37036990
http://dx.doi.org/10.1073/pnas.2205085120

Ejemplares similares